Company type | Sociedad Anónima |
---|---|
BMAD: ALM | |
ISIN | ES0157097017 |
Founded | 1943 |
Founder | Antonio Gallardo Carreras |
Headquarters | |
Area served | International |
Products | Ebglyss, Ilumetri, Wynzora, Klisyri, Seysara, Ebastel, Monodox, Acticlate, Almogran, Tesavel & Efficib, Solaraze, Airtal, Decoderm, Cordran, Almax, Parapres, Balneum, Sativex, Cleboril, Monovo, Actikerall. [1] |
Revenue | €878.5 million (2022) [2] |
€33.5 million (2022) [2] | |
Total assets | €2.302 billion (2022) [2] |
Number of employees | 1,800 (2022) [3] |
Website | www |
Almirall, S.A. is a Spanish pharmaceutical company dedicated to medical dermatology, with headquarters in Barcelona, founded in 1944. [4]
In 2022, the company generated total revenues of €878.5 [5] million and was the leading European company in medical dermatology.
With approximately 1,800 employees (2022), it has a direct presence in 20 countries through its 15 subsidiaries in Europe and the USA. [6]
Almirall SA was founded in 1944 in Spain. In 1979, the company launched gastroprokinetic clebopride in Spain, the first product from the company’s internal R&D team. In 1984, the business launched antacid product, almagate, in Spain, as well as anti-inflammatory piketoprofen in 1985 and antihistamine ebastine and cinitapride in 1985. In the same year, Almirall opened its first subsidiary, based in Belgium. In 1992 the company launched aceclofenac and a year later opened its second foreign subsidiary, in Portugal. The company's new headquarters were opened in Barcelona, in 1994. In 1997 Almirall and Prodesfarma merged their interests. [7]
In 2000 the FDA approved anti-migraine agent almotriptan. A year later the company opened its Mexican subsidiary as well as acquiring its French affiliate. Beginning in 2002, Almirall opened a series of European based subsidiaries; Italy (2002), Germany (2003), Austria, Poland, the United Kingdom, Ireland and Switzerland (2008), Nordic Countries (2010) [8] and Netherlands (2013).
In 2005 the business acquired the commercial rights for Sativex in Europe for the treatment of spasticity associated to multiple sclerosis. In 2006, the company opened its new R&D Centre based in Sant Feliu de Llobregat as well as the acquisition of the Centre of Excellence for Inhalation Technology.
In 2007, the company floated on the Spanish stock market, as well as acquiring European dermatology specialist, Hermal. The company also acquired a portfolio of eight products from Shire plc.
In 2011, Almirall launched Actikerall prescribed for the local treatment of actinic keratosis.
In 2012, Almirall opened its first North America subsidiary, based in Canada [8] and launched aclidinium, prescribed for chronic obstructive pulmonary disease (COPD), in Europe under the brand Eklira Genuair and Bretaris Genuair and in the United States under the brand Tudorza Pressair. The business also launched Monovo, for the treatment of inflammatory skin diseases such as psoriasis.
Almirall began a concentrated focus on medical dermatology in 2013 [9] , following the acquisition of another specialist dermatology company, Aqua Pharmaceuticals. The company launched linaclotide in Europe (Constella) for irritable bowel syndrome with constipation (IBS-C) and opened its Netherlands subsidiary. [8]
In 2014 Almirall divested its rights to its respiratory franchise to Astrazeneca focussing on the dermatology, later in 2015 declaring its strategic intention to become a leading pharmaceutical company in the field of dermatology and continuing with its expansion by acquiring Poli Group Holding and ThermiGen LLC in 2016 [10] .
In January 2020, the company announced it would acquire Bioniz Therapeutic. [11] [12] In 2020, Almirall earned 74.3 million euros, 30% less than the previous year. The following year it closed with a loss of 40.9 million. According to the annual accounts, the losses were justified by the accounting impairment of various products, although sales grew by 2.5%, driven by the dermatology business. In February 2022 it was announced that Carlos Gallardo would replace his father, Jorge Gallardo, as president of the company. [13]
Almirall collaborates with various public and private entities, such as the Centro Superior de Investigaciones Científicas (CSIC), the Instituto de Investigación Biomédica and the Parc Científic de Barcelona [14] in Spain. Highlighted among the international alliances are those with the Imperial College London (United Kingdom) and the National Institute of Health (NIH) in the United States. Almirall participated in the creation of the Barcelona Respiratory Network Foundation. [15] In Europe, the company has contributed in several projects with the Innovative Medicines Initiative (IMI).
The R&D centre in Sant Feliu de Llobregat (Barcelona), houses the departments involved in all stages of R&D, as well as the development of new chemical entities. The Reinbek Centre of Excellence for Dermatology specializes in the development of new formulas for the treatment of skin diseases.
The company also has three production centres: two in Spain, the pharmaceutical plant in Sant Andreu de la Barca (Barcelona) and the pharmaceutical and chemical plant in Sant Celoni (Barcelona); and a pharmaceutical plant in Germany (Reinbek); as well as 13 affiliates in Germany, Austria, Belgium-Luxembourg, the United States, France, the Netherlands, Italy, the Nordic countries, Poland, Portugal, the United Kingdom-Ireland, Spain, and Switzerland. [16]
2010 | 2011 | 2012 | 2013 | 2014 [17] | 2015 [18] | 2016 [19] | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total revenue | €1002,1 MM | €873,1 MM | €900,2 MM | €825,5 MM | €1.407,4 MM | €769 MM | €859,3 MM | €755,8 MM | €811,0 MM | €908,4 MM | €814,5 MM | €836,5 MM | €878,5 MM |
Net sales | €882.4 MM | €768.4 MM | €682.9 MM | €692.9 MM | €786.4 MM | €685 MM | €764,4 MM | €639,4 MM | €756,9 MM | €853,1 MM | €807,4 MM | €827,2 MM | €863,2 MM |
% International sales | - | 50% | 60% | 62% | 70% | 68% | 70% | 69% | |||||
% Sales of own medicines | - | - | 59% | 64% | 70% | 67% | 77% | 68% | |||||
Investment in R&D [20] | 16.4% of net sales | 18.8% of net sales | 23.4% of net sales | 18% of net sales | 12.8% of net sales | 9.7% of net sales | 12,9% of net sales | 13,7% of net sales | 11,6% of net sales | 10,8% of net sales | 10% of net sales | 9% de of net sales | 12% of net sales |
Employees | 2,831 | 2,765 | 2,871 | 3,000 | 2,100 | 1,889 | 1,975 | 1.832 | 1.805 | 1.765 | 1.785 | 1.786 | 1.845 |
Affiliates | 13 | 13 | 14 | 15 | 14 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 15 |
R&D Centres [21] | 3 | 3 | 3 | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 2 | 1 |
Production centres | 3 | 3 | 3 | 3 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 |
Brand | Active ingredient | Pathology |
---|---|---|
Ebastel | Ebastine | Allergy |
Monodox | Doxycycline | Severe Acne |
Acticlate | Doxycycline hyclate | Severe Acne |
Almogran | Almotriptan | Migraine |
Tesavel and Efficib | Sitagliptin and sitagliptin/metformin | Diabetes |
Solaraze | Diclofenac sodium | Actinic keratosis |
Airtal | Aceclofenac | Musculoskeletal pain |
Decoderm | Fluprednidene | Fungal dermatitis |
Cordran | Fludroxycortide | Inflammation and itching of the skin |
Parapres | Candesartan | Hypertension |
Almax | Almagate | Acidity |
Balneum | Urea | Dry skin |
Cleboril | Clebopride | Gastroesophageal reflux disease |
Actikerall | 5-Fluorouracil / salicylic acid | Actinic keratosis |
Sativex | Nabiximols | Spasticity in Multiple Sclerosis |
Monovo | Mometasone | Psoriasis |
Ilumetri | Tildrakizumab | Psoriasis |
Ebglyss | Lebrikizumab | Atopic Dermatitis |
Wynzora | Calcipotriol/Betamethasone | Psoriasis |
Klisyri | Tirbanibulin | Actinic keratosis |
Seysara | Sarecycline | Acne |
Physiorelax | Helenalin | Muscle and ligament massage |
Barcelona is a city on the northeastern coast of Spain. It is the capital and largest city of the autonomous community of Catalonia, as well as the second-most populous municipality of Spain. With a population of 1.6 million within city limits, its urban area extends to numerous neighbouring municipalities within the province of Barcelona and is home to around 4.8 million people, making it the fifth most populous urban area in the European Union after Paris, the Ruhr area, Madrid and Milan. It is one of the largest metropolises on the Mediterranean Sea, located on the coast between the mouths of the rivers Llobregat and Besòs, bounded to the west by the Serra de Collserola mountain range.
Vallès Occidental is a comarca (county) in the Barcelona region in Catalonia (Spain). It has two capitals, Sabadell and Terrassa. Along with Vallès Oriental, it forms the historical Vallès region.
The Trambaix is one of Barcelona's three tram systems. It is operated by TRAMMET connecting the Baix Llobregat area with the city of Barcelona, Catalonia, Spain. It opened to the public on 5 April 2004 after a weekend when the tram could be used free of charge.
Glénat Éditions SA is a French publisher with its head office in Grenoble. Their products include comic albums and manga in France, Benelux, and in the past Spain; it was founded by Jacques Glénat. The Benelux subsidiary, Glénat Benelux N.V., is located in Brussels, Belgium. The Switzerland subsidiary, Glénat Éditions (Suisse) SA, has its headquarters in Nyon. The Spanish subsidiary had its head office in Barcelona.
Serono was a biotechnology company headquartered in Geneva, Switzerland. It was acquired by the German pharmaceutical company Merck in 2006. The company was founded as the Serono Pharmacological Institute by Cesare Serono in 1906 in Rome, Italy. A key step in its development was the discovery of a method of extracting urinary gonadotropins by Dr. Piero Donini. Serono was incorporated in 1987 and the holding company, Ares-Serono S.A., changed its name to Serono S.A. in May 2000.
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.
Sant Feliu de Llobregat is an industrial city and municipality in Catalonia, Spain, in the province of Barcelona. It is the capital of the comarca of Baix Llobregat, and the see of a bishopric since June 2005.
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on transformative medicines in three therapeutic areas: oncology, rare disease and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Bradley Pharmaceuticals was a pharmaceutical company headquartered in Fairfield Township, Essex County, New Jersey. The company was founded in 1985 by Daniel Glassman who was also its CEO.
Bicing is a bicycle-sharing system in the city of Barcelona, Catalonia, Spain, which was implemented in March 2007, promoted by the City Council. The municipal company Barcelona de Serveis Municipals (B:SM) is the manager of the service, while the exploitation concession corresponds to Pedalem Barcelona since 2019, a Temporary Union of Companies formed by CESPA and PBSC. Between 2007 and 2018, Clear Channel was the company in charge of this task. It is similar to the Vélo'v service in Lyon or Vélib' in Paris, and uses the same bicycles and stations as used in Stockholm, Oslo, and Zaragoza. Its purpose is to cover small and medium daily routes within the city in a climate-friendly way, eliminating the pollution, roadway noise, and traffic congestion that motor vehicles create.
Grifols, S.A. is a Spanish multinational pharmaceutical and chemical manufacturer. Principally a producer of blood plasma–based products, a field in which it is the European leader and largest worldwide, the company also supplies devices, instruments, and reagents for clinical testing laboratories.
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynecology, respiratory, oncology, dental and nutritionals.
The Sant Feliu de Guíxols to Girona Railway was a 750 mm gauge railway line that operated over 42 kilometres (26 mi) of track between Girona and Sant Feliu de Guíxols, in Catalonia, Spain. The railway had 6 steam locomotives of the 0-6-2T type, 21 passenger cars and 106 freight cars.
Linaclotide, is a drug used to treat irritable bowel syndrome with constipation and chronic constipation with no known cause. It has a black box warning about the risk of serious dehydration in children in the US; the most common adverse effects in others include diarrhea.
Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.
Historically, the city of Barcelona, in the Spanish autonomous community of Catalonia, had a large tramway network. The city's first tram line opened in 1872, but almost all of these historic lines had closed by 1971, being replaced by buses and by the expanding Barcelona Metro. The one remaining line, the Tramvia Blau, was retained as tourist attraction, using historic rolling stock. However at the beginning of the 21st century, two new tram systems, the Trambaix and Trambesòs, opened in the suburbs of the city.
Vianex S.A. is a Greek pharmaceutical company, founded in 1971 by the Giannakopoulos’ family that has been involved with the pharmaceutical industry since 1924.
Antoni Vila Casas was a Spanish pharmaceutical executive and philanthropist.
The Autopista B-23 or Accés a Barcelona centre is a Spanish motorway that goes from Avinguda Diagonal, in Barcelona City, with the AP-7. It is located in Catalonia and has a length of 15.5 kilometres (9.6 mi). It is part of the European route E90.
HIPRA is a biotech pharmaceutical company headquartered in Amer, Catalonia, Spain focused on prevention for animal and human health, with a product base of vaccines and diagnostic services.
{{cite web}}
: CS1 maint: archived copy as title (link){{cite web}}
: CS1 maint: archived copy as title (link){{cite web}}
: CS1 maint: archived copy as title (link)